2,4-Diisopropyl-anisol | 92100-76-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Diisopropyl-anisol
• 英文别名: 2,4-diisopropyl-anisole；1-Methoxy-2,4-di(propan-2-yl)benzene
• CAS: 92100-76-0
• 化学式: C₁₃H₂₀O
• 分子量: 192.301
• InChiKey: YLAMSSZTXPXPMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲苯 、 硫酸二甲酯 作用下， 生成 2,4-Diisopropyl-anisol
  参考文献：
  名称：

  NITRO MUSKS. I. ISOMERS, HOMOLOGS, AND ANALOGS OF MUSK AMBRETTE

  摘要：

  DOI：

  10.1021/jo01144a011

文献信息

• WDR5-MLL1 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200055824A1

  公开（公告）日：2020-02-20

  Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.

  苯甲酰胺和吡啶甲酰胺，它们在间位被亚胺基、胍基或含杂环基团取代，会破坏WDR5-MLL1蛋白质间相互作用，并可用于制药组合物中，用于治疗受试者中的增殖性疾病和状况，如癌症。
• PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF
  申请人：Zhao Guilong

  公开号：US20130023486A1

  公开（公告）日：2013-01-24

  The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of R 5 and R 6 are selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H.

  该发明涉及一种具有苯基C-葡萄苷结构的钠葡萄糖共转运蛋白2（SGLT2）抑制剂，其制备方法，含有该抑制剂的药物组合物，以及其在治疗糖尿病和制备抗糖尿病药物中的用途。该发明提供了一种具有一般式I结构的化合物及其药用盐和前药酯，其中，R5和R6的定义从以下选定：（1）R5=R6=Me；（2）R5=Me，R6=OMe；（3）R5=Me，R6=H；（4）R5=Me，R6=F；（5）R5=F，R6=H；和（6）R5=OMe，R6=H。
• N-Phenyloxamide derivatives
  申请人：YAMAGUCHI Youichi

  公开号：US20080249175A1

  公开（公告）日：2008-10-09

  A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R 1 represents a C 6-10 aryl group; or a C 6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, cyano group, nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group and a C 1-6 alkylsulfanyl group, R 2 represents a C 6-10 aryl group; or a C 6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, hydroxy group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a C 1-6 alkylsulfanyl group and phenyl group, X represents a single bond or oxygen atom, Z represents a phenylene group or a substituted phenylene group, m represents 0 or 1.

  由以下一般式(I)表示的化合物或其盐，或其水合物或其溶剂合物，具有对纤溶酶原激活酶抑制剂-1（PAI-1）的抑制作用：其中R1表示一个C6-10芳基团；或一个C6-10芳基团，该芳基团取代为从卤原子、氰基、硝基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基和C1-6烷基硫基等组成的组或组合物，R2表示一个C6-10芳基团；或一个C6-10芳基团，该芳基团取代为从卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基和苯基等组成的组或组合物，X表示一个单键或氧原子，Z表示一个苯基或取代苯基，m表示0或1。
• NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：DeLucca George V.

  公开号：US20120082702A1

  公开（公告）日：2012-04-05

  Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds.

  本发明涉及一种公式（I）的烟酰胺化合物，或其立体异构体或其药学上可接受的盐。还公开了使用这种化合物治疗至少一种Btk相关疾病的方法，例如炎症性疾病，并且还公开了包含这种化合物的药物组合物。
• Cholesteryl Ester Transfer Protein Inhibitors
  申请人：Ali Amjad

  公开号：US20100167986A1

  公开（公告）日：2010-07-01

  Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A 1 and A 2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring, and Z is an aromatic or heterocyclic ring.

  式(I)的化合物，包括该化合物的药学上可接受的盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于预防或治疗动脉粥样硬化。在式(I)的化合物中，A1和A2均为芳香环，5-6成员杂环环，芳香环与杂环环融合，苯环与杂环环融合或环烷基环，而Z为芳香环或杂环环。